Drug Profile
Tapinarof - Beijing Wenfeng Tianji Pharmaceuticals/Dermavant Sciences/Japan Tobacco/Torii Pharmaceuticals
Alternative Names: Benvitimod; DHPS; DMVT 505; GSK-2894512; VTAMA; WBI-1001; XinbikeLatest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Welichem Biotech
- Developer Beijing Wenfeng Tianji Pharmaceuticals; Dermavant Sciences; Japan Tobacco; Torii Pharmaceutical; Welichem Biotech
- Class Anti-inflammatories; Antipsoriatics; Nonsteroidal anti-inflammatories; Resorcinols; Skin disorder therapies; Small molecules; Stilbenes
- Mechanism of Action Aryl hydrocarbon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Plaque psoriasis
- Preregistration Atopic dermatitis
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 14 Feb 2024 Preregistration for Atopic dermatitis (In adolescents, In children, In the elderly, In adults) in USA (Topical)
- 13 Feb 2024 Roivant sciences announces intention to file sNDA to US FDA for Atopic dermatitis in H2 of 2024
- 11 Jan 2024 Interim adverse events and efficacy data from a phase III ADORING 3 trial in Atopic dermatitis released by Dermavant Sciences